Protocol Ledger

NCT07287670 · Phase II · RECRUITING

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Interventional Phase II clinical trial protocol NCT07287670 sponsored by Mediar Therapeutics in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-16 Enrollment: 85 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07287670
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)85 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07287670
Protocol FieldVerified Registry Value
NCT IdentifierNCT07287670
Consolidated Lead SponsorMediar Therapeutics
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment85 participants (ESTIMATED)
Registered Start Date2026-04-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI